Serum tartrate-resistant acid phosphatase 5b in monitoring bisphosphonate treatment with clodronate: A comparison with urinary N-terminal telopeptide of type I collagen and serum type I procollagen amino-terminal propeptide

Osteoporosis International

Volumn 16, Issue 9, 2005, Pages 1109-1116

  Tähtelä, Riitta ^a   Seppanen J ^b   Laitinen, K ^c   Katajamaki A ^d   Risteli, J ^e   Valimaki M J ^c,d  

^a Mehilainen Oy   (Finland)

^b FINNISH CANCER REGISTRY   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d Yhtyneet Laboratoriot Oy   (Finland)

^e OULU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Clodronate; NTX; Osteoporosis; PINP; TRACP 5b; Treatment

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; COLLAGEN TYPE 1; CREATININE; PROCOLLAGEN C PROTEINASE; TELOPEPTIDE;

ADULT; ARTICLE; BONE DENSITY; CALCULATION; CLINICAL TRIAL; COLLAGEN SYNTHESIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MARKER; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; ENZYME ACTIVITY; FEMALE; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MEASUREMENT; MULTICENTER STUDY; OSSIFICATION; OSTEOCLAST; OSTEOLYSIS; OSTEOPENIA; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN DEGRADATION; RANDOMIZED CONTROLLED TRIAL; SERUM; URINALYSIS; URINARY EXCRETION;

ACID PHOSPHATASE; BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; CLODRONIC ACID; COLLAGEN; COLLAGEN TYPE I; DOUBLE-BLIND METHOD; DRUG MONITORING; FEMALE; FEMUR; FEMUR NECK; FOLLOW-UP STUDIES; HUMANS; ISOENZYMES; LUMBAR VERTEBRAE; MIDDLE AGED; PEPTIDE FRAGMENTS; PEPTIDES; POSTMENOPAUSE; PROCOLLAGEN; TREATMENT OUTCOME;

EID: 24044482954     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-004-1819-7     Document Type: Article

References (50)

1. Risteli L, Risteli J (1993) Biochemical markers of bone metabolism. Ann Med 25:385-393
2. Blumsohn A, Eastell R (1997) The performance and utility of biochemical markers of bone turnover: do we know enough to use them in clinical practice? Ann Clin Biochem 34:449-459
3. Seibel MJ (2000) Molecular markers of bone turnover: Biochemical, technical and analytical aspects. Osteoporos Int 10 [Suppl 6]:S18-29
4. Hannon R, Blumsohn A, Naylor K, Eastell R (1998) Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability. J Bone Miner Res 13:1124-1133
5. Melton LJ 3rd, Khosla S, Atkinson EJ, O'Fallon WM, Riggs BL (1997) Relationship of bone turnover to bone density and fractures. J Bone Miner Res 12:1083-1091
6. Garnero P, Dargent-Molina P, Hans D, Schott AM, Bréart G, Meunier PJ, Delmas PD (1998) Do markers of bone resorption add to bone mineral density and ultrasonographic heel measurement for the prediction of hip fracture in elderly women? The EPIDOS prospective study. Osteoporos Int 8:563-569
7. Bauer DC, Sklarin PM, Stone KL, Black DM, Nevitt MC, Ensrud KE, Arnaud CD, Genant HK, Garnero P, Delmas PD, Lawaetz H, Cummings SR for the study of osteoporotic fractures research group (1999) Biochemical markers of bone turnover and prediction of hip bone loss in older women: the study of osteoporotic fractures. J Bone Miner Res 14:1404-1410
8. Marcus R, Holloway L, Wells B, Greendale G, James MK, Wasilauskas C, Kelaghan J (1999) The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. J Bone Miner Res 14:1583-1595
9. Rosen CJ, Chesnut CH 3rd, Mallinak NJS (1997) The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation. J Clin Endocrinol Metab 82:1904-1910
10. Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsay L, Karpf DB (1998) Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial. J Bone Miner Res 13:1431-1438
11. Ravn P, Hosking D, Thompson D, Cizza G, Wasnich RD, McClung M et al (1999) Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. J Clin Endocrinol Metab 84:2363-2368
12. Hassager C, Risteli J, Risteli L, Jensen SB, Christiansen (1992) Diurnal variation in serum markers of type I collagen synthesis and degradation in healthy premenopausal women. J Bone Miner Res 7:1307-1311
13. Blumsohn A, Herrington K, Hannon RA, Shao P, Eyre DR, Eastell R (1994) The effect of calcium supplementation on the circadian rhythm of bone resorption. J Clin Endocrinol Metab 79:730-735
14. Panthegini M, Pagani F (1996) Biological variation in urinary excretion of pyridinium crosslinks: recommendations for the optimum specimen. Ann Clin Biochem 33:36-42
15. Woitge HW, Pecherstorfer M, Li Y, Keck A-V, Horn E, Ziegler R, Seibel M (1999) Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices. J Bone Miner Res 14:792-801
16. Rosen HN, Moses AC, Garber J, Iloputaife ID, Ross DS, Lee SL, Greenspan SL (2000) Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int 66:100-103
17. Christgau S, Bitsch-Jensen O, Hanover Bjarnason N, Gamwell Henriksen E, Qvist P, Alexandersen P, Bang Henriksen D (2000) Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy. Bone 26:505-511
18. Clowes JA, Hannon RA, Yap TS, Hoyle NR, Blumsohn A, Eastell R (2002) Effect of feeding on bone turnover markers and its impact on biological variability of measurements. Bone 30:886-890
19. Prockop DJ, Kivirikko KI, Tuderman L, Guzman RA (1979) The biosynthesis of collagen and its disorders. N Engl J Med 301:13-23, 77-85
20. Smedsrod B, Melkko J, Risteli L, Risteli J (1990) Circulating C-terminal propeptide of type I procollagen is cleared mainly via the mannose receptor in liver endothelial cells. Biochem J 271:345-350
21. Melkko J, Hellevik T, Risteli L, Risteli J, Smedsrod B (1994) Clearance of the amino-terminal propeptides of types I and III procollagen is a physiological function of the scavenger receptor in liver endothelial cells. J Exp Med 179:405-412
22. Blom E, Ali MM, Mortensen B, Huseby NE (1998) Elimination of alkaline phosphatases from circulation by the galactose receptor. Different isoforms are cleared at various rates. Clin Chim Acta 270:125-136
23. Minkin C (1982) Bone acid phosphatase: tartrate-resistant acid phosphatase as a marker of osteoclast function. Calcif Tissue Int 34:285-290
24. Clark SA, Ambrose WW, Anderson TR, Terrell RS, Toverud SU (1989) Ultrastructural localization of tartrate-resistant, purple acid phosphatase in rat osteoclasts by histochemistry and immunocytochemistry. J Bone Miner Res 5:399-405
25. Andersson G, Ek-Rylander B (1995) The tartrate-resistant purple acid phosphatase of bone osteoclasts - a protein phosphatase with multivalent substrate specificity and regulation. Acta Orthop Scand 66 [Suppl 266]:189-194
26. Halleen JM, Kaija H, Stepan JJ, Vihko P, Väänänen HK (1998) Studies on the protein tyrosine phosphatase activity of tartrate-resistant acid phosphatase. Arch Biochem Biophys 352:97-102
27. Halleen JM, Räisänen S, Salo JJ, Reddy SV, Roodman GD, Hentunen TA et al (1999) Intracellular fragmentation of bone resorption products by reactive oxygen species generated by osteoclastic tartrate-resistant acid phosphatase. J Biol Chem 274:22907-22910
28. Lam KW, Eastlund DT, Li CY, Yam LT (1978) Biochemical properties of tartrate-resistant acid phosphatase in serum of adults and children. Clin Chem 24:1105-1108
29. Halleen JM, Alatalo SA, Suominen H, Cheng S, Janckila AJ, Väänänen HK (2000) Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption. J Bone Miner Res 15:1337-1345
30. Hannon RA, Clowes JA, Eagleton AC, Al Hadari A, Eastell R, Blumsohn A (2004) Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption. Bone 34:187-194
31. Välimäki MJ, Laitinen K, Patronen A, Puolijoki H, Seppänen J, Pylkkänen L et al for the Probone Study Group (2002) Prevention of bone loss by clodronate in early postmenopausal women with vertebral osteopenia: a dose-finding study. Osteoporos Int 13:937-947
32. Garnero P, Hih WJ, Gineyts E, Karpf DB, Delmas PD (1994) Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 79:1693-1700
33. Dominguez Cabrera C, Sosa Henriques M, Traba ML, Alvarez Villafane E, de la Piedra C (1998) Biochemical markers of bone formation in the study of postmenopausal osteoporosis. Osteoporos Int 8:147-151
34. Peris P, Alvarez L, Monegal A, Guanabens N, Duran M, Pons F et al (1999) Biochemical markers of bone turnover after surgical menopause and hormone replacement therapy. Bone 25:349-353
35. Halleen JM, Alatalo SA, Janckila AJ, Woitge HW, Seibel MJ, Väänänen HK (2001) Serum tartrate-resistant acid phosphatase 5b is a specific and sensitive marker of bone resorption. Clin Chem 47:597-600
36. Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Mönkkönen J, Frith JC (2000) Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88:2961-2978
37. Selander KS, Mönkkönen J, Karhukorpi EK, Härkönen P, Hannuniemi R, Väänänen HK (1996) Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages. Mol Pharmacol 50:1127-1138
38. Lehenkari PP, Kellinsalmi M, Napankangas JP, Ylitalo KV, Mönkkönen J, Rogers MJ et al (2002) Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol 61:1255-1262
39. Teronen O, Heikkilä P, Konttinen YT, Laitinen M, Salo T, Hanemaaijer R et al (1999) MMP inhibition and downregulation by bisphosphonates. Ann N Y Acad Sci 878:453-465
40. Halasy-Nagy JM, Rodan GA, Reszka AA (2001) Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis. Bone 29:553-559
41. Stepan JJ, Burckhardt P (2002) Serum activity of type 5b ACP and biochemical markers of type I collagen degradation in osteoporotic men with Klinefelter's syndrome treated with intravenous ibandronate. Calcif Tissue Int 70:279, P78
42. Hofbauer LC, Khosla S, Dunstan CR, Lacey D, Boyle WJ, Riggs BL (2000) The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 15:2-12
43. Shevde NK, Bendixen AC, Dienger KM, Pike JW (2000) Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. Proc Natl Acad Sci U S A 97:7829-7834
44. Stepan JJ, Vokrouhlicka J (1999) Comparison of biochemical markers of bone remodelling in the assessment of the effects of alendronate on bone in postmenopausal osteoporosis. Clin Chim Acta 288:121-135
45. Garnero P, Gineyts E, Arbault P, Christiansen C, Delmas PD (1995) Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion. J Bone Miner Res 10:641-649
46. Bjarnason NH, Sarkar S, Duong T, Mitlak B, Delmas PD, Christiansen C (2001) Six and 12-month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int 12:922-930
47. Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J, Thompson DE, Ewing SK, Delmas PD, The Fracture Intervention Trial Study Group (2004) Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: The Fracture Intervention Trial. J Bone Miner Res 19:1250-1258
48. Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD (2003) Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 18:1051-1056
49. Li Z, Meredith MP, Hoseyni MS (2002) A method to assess the proportion of treatment effect explained by a surrogate end-point. Stat Med 20:3175-3188
50. McCloskey E, Selby P, Davies M, Robinson J, Francis RM, Adams J, Kayan K, Beneton M, Jalava T, Pylkkanen L, Kenraali J, Aropuu S, Kanis JA (2004) Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study. J Bone Miner Res 19:728-736